Procyclidine
Kemadrin (procyclidine) is a small molecule pharmaceutical. Procyclidine was first approved as Kemadrin on 1982-01-01. It is used to treat parkinsonian disorders in the USA.
Download report
Favorite
Commercial
Therapeutic Areas
Therapeutic Area | MeSH |
|---|---|
| nervous system diseases | D009422 |
Trade Name
FDA
EMA
No data
Drug Products
FDA
EMA
New Drug Application (NDA)
New Drug Application (NDA)
Abbreviated New Drug Application (ANDA)
Abbreviated New Drug Application (ANDA)
Procyclidine hydrochloride
Tradename | Company | Number | Date | Products |
|---|---|---|---|---|
| KEMADRIN | Monarch Pharmaceuticals | N-009818 DISCN | 1982-01-01 | 2 products |
Hide discontinued
Labels
FDA
EMA
No data
Indications
FDA
EMA
Indication | Ontology | MeSH | ICD-10 |
|---|---|---|---|
| parkinsonian disorders | HP_0001300 | D020734 | — |
Agency Specific
FDA
EMA
No data
Patent Expiration
No data
HCPCS
No data
Clinical
Clinical Trials
22 clinical trials
View more details
Mock data
Subscribe for the real data
Subscribe for the real data
Indications Phases 4
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Migraine disorders | D008881 | EFO_0003821 | G43 | 1 | 1 | 2 | 3 | 1 | 8 |
| Vomiting | D014839 | HP_0002013 | R11.1 | — | 1 | 1 | 1 | — | 3 |
| Headache | D006261 | HP_0002315 | R51 | — | — | 1 | 2 | — | 3 |
Indications Phases 3
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Nausea | D009325 | HP_0002018 | R11.0 | — | — | 1 | — | — | 1 |
| Female genital neoplasms | D005833 | — | — | 1 | — | — | 1 | ||
| Breast neoplasms | D001943 | EFO_0003869 | C50 | — | — | 1 | — | — | 1 |
| Neoplasms | D009369 | C80 | — | — | 1 | — | — | 1 | |
| Facial neuralgia | D005156 | EFO_0009380 | 351.8 | — | — | 1 | — | — | 1 |
Indications Phases 1
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Cardiotoxicity | D066126 | EFO_1001482 | 1 | — | — | — | — | 1 | |
| Healthy volunteers/patients | — | 1 | — | — | — | — | 1 | ||
| Multiple myeloma | D009101 | C90.0 | 1 | — | — | — | — | 1 |
Indications Without Phase
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Schizophrenia | D012559 | EFO_0000692 | F20 | — | — | — | — | 1 | 1 |
Epidemiology
Epidemiological information for investigational and approved indications
View more details
Drug
General
| Drug common name | PROCYCLIDINE |
| INN | procyclidine |
| Description | Procyclidine is an anticholinergic drug principally used for the treatment of drug-induced parkinsonism, akathisia and acute dystonia, Parkinson's disease, and idiopathic or secondary dystonia.
|
| Classification | Small molecule |
| Drug class | muscarinic receptor agonists/antagonists |
| Image (chem structure or protein) | |
| Structure (InChI/SMILES or Protein Sequence) | OC(CCN1CCCC1)(c1ccccc1)C1CCCCC1 |
Identifiers
| PDB | — |
| CAS-ID | 77-37-2 |
| RxCUI | — |
| ChEMBL ID | CHEMBL86715 |
| ChEBI ID | 8448 |
| PubChem CID | 207841 |
| DrugBank | DB00387 |
| UNII ID | C6QE1Q1TKR (ChemIDplus, GSRS) |
Target
Agency Approved
No data
Alternate
No data
Variants
Clinical Variant
No data
Financial
No data
Trends
PubMed Central
Top Terms for Disease or Syndrome:
Mock data
Subscribe for the real data
Subscribe for the real data
Additional graphs summarizing 610 documents
View more details
Safety
Black-box Warning
No Black-box warning
Adverse Events
Top Adverse Reactions
Mock data
Subscribe for the real data
Subscribe for the real data
2,470 adverse events reported
View more details
Premium feature
Learn more about premium features at pharmakb.com
Learn more